Mutual of America Capital Management LLC Has $4.25 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)
Mutual of America Capital Management LLC lowered its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 2.5% during the fourth quarter, Holdings Channel reports. The fund owned 358,819 shares of the company’s stock after selling 9,047 shares during the period. Mutual of America Capital Management LLC’s holdings in Roivant Sciences were worth $4,245,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in ROIV. TOMS Capital Investment Management LP bought a new stake in Roivant Sciences during the 3rd quarter worth about $46,333,000. FMR LLC grew its holdings in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after acquiring an additional 2,593,910 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after purchasing an additional 1,460,205 shares during the last quarter. State Street Corp boosted its stake in shares of Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after purchasing an additional 1,118,561 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Roivant Sciences by 49.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company’s stock valued at $26,625,000 after purchasing an additional 762,953 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.
Roivant Sciences Price Performance
Roivant Sciences stock opened at $10.70 on Thursday. The company’s 50 day simple moving average is $11.01 and its 200 day simple moving average is $11.57. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06. The firm has a market capitalization of $7.63 billion, a price-to-earnings ratio of -71.33 and a beta of 1.25.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Analysts Set New Price Targets
Several brokerages have recently issued reports on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $18.08.
Get Our Latest Research Report on Roivant Sciences
Insider Buying and Selling
In related news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Rakhi Kumar sold 227,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,388,170 shares of company stock valued at $27,612,299 in the last 90 days. 7.90% of the stock is owned by insiders.
Roivant Sciences Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Recommended Stories
Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).
Receive News & Ratings for Roivant Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Roivant Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.